BIOTEST AG (BIO.DE) Stock Fundamental Analysis
Europe - FRA:BIO - DE0005227201 - Common Stock
42.2 EUR
-0.4 (-0.94%)
Taking everything into account, BIO scores 4 out of 10 in our fundamental rating. BIO was compared to 73 industry peers in the Biotechnology industry. Both the profitability and the financial health of BIO get a neutral evaluation. Nothing too spectacular is happening here. BIO has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BIO has reported negative net income.
In the past year BIO had a positive cash flow from operations.
In multiple years BIO reported negative net income over the last 5 years.
In multiple years BIO reported negative operating cash flow during the last 5 years.
1.2 Ratios
BIO has a Return On Assets of -1.73%. This is in the better half of the industry: BIO outperforms 66.67% of its industry peers.
BIO has a Return On Equity of -4.81%. This is in the better half of the industry: BIO outperforms 68.06% of its industry peers.
The Return On Invested Capital of BIO (0.54%) is better than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.73% | ||
| ROE | -4.81% | ||
| ROIC | 0.54% |
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of BIO (1.87%) is better than 75.00% of its industry peers.
In the last couple of years the Operating Margin of BIO has grown nicely.
With a Gross Margin value of 23.19%, BIO perfoms like the industry average, outperforming 51.39% of the companies in the same industry.
In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.87% | ||
| PM (TTM) | N/A | ||
| GM | 23.19% |
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
The number of shares outstanding for BIO remains at a similar level compared to 1 year ago.
BIO has about the same amout of shares outstanding than it did 5 years ago.
BIO has a better debt/assets ratio than last year.
2.2 Solvency
BIO has an Altman-Z score of 2.36. This is not the best score and indicates that BIO is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.36, BIO is in the better half of the industry, outperforming 70.83% of the companies in the same industry.
BIO has a debt to FCF ratio of 46.44. This is a negative value and a sign of low solvency as BIO would need 46.44 years to pay back of all of its debts.
BIO's Debt to FCF ratio of 46.44 is fine compared to the rest of the industry. BIO outperforms 76.39% of its industry peers.
BIO has a Debt/Equity ratio of 1.26. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of BIO (1.26) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | 46.44 | ||
| Altman-Z | 2.36 |
ROIC/WACC0.09
WACC6.01%
2.3 Liquidity
A Current Ratio of 4.93 indicates that BIO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.93, BIO belongs to the top of the industry, outperforming 81.94% of the companies in the same industry.
A Quick Ratio of 1.66 indicates that BIO should not have too much problems paying its short term obligations.
BIO has a Quick ratio (1.66) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.93 | ||
| Quick Ratio | 1.66 |
3. Growth
3.1 Past
BIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.24%.
BIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.85%.
The Revenue has been growing by 11.62% on average over the past years. This is quite good.
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 27.85, which means the current valuation is very expensive for BIO.
BIO's Price/Forward Earnings ratio is rather cheap when compared to the industry. BIO is cheaper than 80.56% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.99, BIO is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.85 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BIO is valued a bit cheaper than 72.22% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BIO is valued a bit cheaper than the industry average as 77.78% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 115.96 | ||
| EV/EBITDA | 43.06 |
4.3 Compensation for Growth
BIO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a yearly dividend of 0.09%, BIO is not a good candidate for dividend investing.
BIO's Dividend Yield is rather good when compared to the industry average which is at 10.16. BIO pays more dividend than 90.28% of the companies in the same industry.
With a Dividend Yield of 0.09, BIO pays less dividend than the S&P500 average, which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.09% |
5.2 History
The dividend of BIO is nicely growing with an annual growth rate of 14.87%!
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
The dividend of BIO is growing, but earnings are growing more, so the dividend growth is sustainable.
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
FRA:BIO (6/6/2025, 7:00:00 PM)
42.2
-0.4 (-0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.67B
Revenue(TTM)635.20M
Net Income(TTM)-24500000
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.09% |
Yearly Dividend0.04
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.85 | ||
| P/S | 2.63 | ||
| P/FCF | 115.96 | ||
| P/OCF | 115.96 | ||
| P/B | 3.28 | ||
| P/tB | 3.39 | ||
| EV/EBITDA | 43.06 |
EPS(TTM)-0.65
EYN/A
EPS(NY)1.52
Fwd EY3.59%
FCF(TTM)0.36
FCFY0.86%
OCF(TTM)0.36
OCFY0.86%
SpS16.05
BVpS12.88
TBVpS12.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.73% | ||
| ROE | -4.81% | ||
| ROCE | 0.95% | ||
| ROIC | 0.54% | ||
| ROICexc | 0.56% | ||
| ROICexgc | 0.57% | ||
| OM | 1.87% | ||
| PM (TTM) | N/A | ||
| GM | 23.19% | ||
| FCFM | 2.27% |
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y111.24%
ROICexc growth 3YN/A
ROICexc growth 5Y111.29%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
F-Score3
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | 46.44 | ||
| Debt/EBITDA | 12.19 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 0.82 | ||
| Cash Conversion | 27.43% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.93 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 2.36 |
F-Score3
WACC6.01%
ROIC/WACC0.09
Cap/Depr(3y)81.86%
Cap/Depr(5y)79.06%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.3%
EBIT growth 3YN/A
EBIT growth 5Y122.17%
EBIT Next Year825%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.72%
FCF growth 3Y27.05%
FCF growth 5YN/A
OCF growth 1Y114.72%
OCF growth 3Y21.56%
OCF growth 5YN/A
BIOTEST AG / BIO.DE FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.DE.
What is the valuation status of BIOTEST AG (BIO.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to BIOTEST AG (BIO.DE). This can be considered as Fairly Valued.
What is the profitability of BIO stock?
BIOTEST AG (BIO.DE) has a profitability rating of 4 / 10.
What is the expected EPS growth for BIOTEST AG (BIO.DE) stock?
The Earnings per Share (EPS) of BIOTEST AG (BIO.DE) is expected to grow by 1600% in the next year.